Eating spicy foods regularly may extend lifespan
the ONA take:
Eating spicy foods regularly may lower the risk of death from cancer, ischemic disease, and respiratory disease, according to a new observational study published in The BMJ.
For the study, researchers in China analyzed data from a prospective cohort study that included 487,375 adults from various various in China. All participants were between ages 30 and 70 and completed questionnaires about their health and consumption of red meat, vegetables, alcohol, and spicy foods. Participants were followed for an average of 7.2 years.
Results showed that consumption of spicy food 3 to 7 days a week was associated with a 14% reduced risk of death during the follow-up period compared with participants who consumed spicy foods less than once a week. Eating spicy foods once or twice a week was linked with a 10% reduced risk of death compared with those who ate it less than once a week.
Researchers also found that frequent consumption of spicy foods was associated with a reduced risk of death from cancer, ischemic heart disease, and respiratory diseases. This effect was more strongly observed in women than men.
Eating spicy foods regularly may lower the risk of death from cancer, ischemic disease, and respiratory disease.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|